Teva Introduces First Eliquis Rival In UK
Capitalizes On Recent Success In Litigation Over Apixaban With Originator BMS
Teva has capitalized on a recent legal victory in the UK by claiming the first launch of a generic apixaban rival to BMS’ Eliquis.
You may also be interested in...
Still only six weeks into the job, Teva’s new CEO Richard Francis and his senior team are busy working on a refreshed company strategy, as Teva looks to grow its top line in 2023 for the first time in six years.
Generics Bulletin looks back at a selection of the most significant legal stories from 2022, including a major victory in the UK on the Eliquis blood thinner giant and continued action on generic label carve outs, which has the potential to reverberate through the US industry.
European litigation, potential US generic launches and new CEOs are among the headlines in November – amid the ninth annual Global Generics & Biosimilars Awards, in Frankfurt.